Novelix Pharmaceuticals Limited (formerly Trimurthi Limited) reported a return to profitability in Q1FY26, posting a net profit of ₹343.13 lakh for the quarter ended June 30, 2026. This marks a significant turnaround from the net loss of ₹721.08 lakh recorded in the immediately preceding quarter (Q4FY26). The company’s total income from operations grew to ₹386.03 lakh, up from ₹358.66 lakh in the prior quarter and ₹338.83 lakh in the same period last year.

The results were reviewed by the Audit Committee and approved by the Board of Directors on August 14, 2026. Statutory auditors issued an unmodified conclusion on the limited review of the unaudited financial results. The company published the extract of its standalone financial results in The Business Standard (English) and The Nirbhaya Vaartha (Telugu) on August 15, 2026, as per SEBI LODR regulations.

Financial Performance

Revenue growth remained steady across periods, with total income from operations increasing sequentially and annually. The full-year revenue for FY26 stood at ₹1,376.59 lakh. Earnings per share (EPS) improved to ₹2.32 for the current quarter, compared to a negative EPS of (₹4.88) in the previous quarter and ₹3.01 in Q1FY25.

What the Numbers Show

The divergence between the strong year-on-year revenue growth and the sequential volatility in profitability highlights the impact of specific accounting adjustments. While revenue expanded consistently, the company recorded a significant net loss in Q4FY26 before returning to profit in Q1FY26. Management noted that during the quarter, the company revised the estimated remaining useful life of certain buildings proposed for demolition as part of a redevelopment plan. This change resulted in a higher depreciation charge provided prospectively over the revised useful life, impacting the bottom line. Despite this increased depreciation expense, the company managed to deliver a positive net profit, suggesting underlying operational resilience.

Equity share capital remained unchanged at ₹1,517.77 lakh with a face value of ₹10 per share. Reserves as shown in the audited balance sheet of the previous year stood at ₹9,813.68 lakh.

Novelix Pharmaceuticals disclosed on July 13, 2026, that its promoters and promoter group increased their shareholding through the conversion of warrants into equity shares. The allotment, which occurred on July 9, 2026, was executed via a preferential offer basis as required under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. This adjustment significantly alters the capital structure and promoter stakes within the company.

The total voting capital of Novelix Pharmaceuticals stands at 28,470,000 equity shares following the transaction. The conversion involved multiple acquirers, including Srinidhi Fine Chemicals LLP, Nanhari Belide, Vupparapalli Chandrasekhar Reddy, and Neha Gattu. The disclosures were submitted to BSE Limited by Venkateshwarlu Pulluri, Whole-time Director, on behalf of the company.

Shareholding Changes

The table below details the specific changes in holdings for the key acquirers, reflecting the movement from pre-allotment to post-allotment positions.

Srinidhi Fine Chemicals LLP acquired 2,100,000 shares at a value of ₹4,20,00,000, while Vupparapalli Chandrasekhar Reddy acquired 775,000 shares valued at ₹15,50,00,000. Nanhari Belide added 400,000 shares worth ₹8,00,00,000, and Neha Gattu acquired 100,000 shares valued at ₹2,00,00,000. The company confirmed that no trading in derivatives was conducted by these individuals during this period.